Fighting cancer by targeting tumor-enhancing mutations.


At Z53 Therapeutics, we are designing first-in-class novel therapeutics to target tumors with mutations in the tumor supressor gene, p53. By developing zinc metallochaperones as drugs, we aim to reactivate the function of mutant p53 protein in cancer cells through restoration of p53 zinc binding and folding. If successful, this novel class of anticancer agents will be one of the first therapeutics to target mutant p53.



Find out more about our breakthrough oncology discovery.

Learn More →


Meet our drug development experts.

Learn More →